In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine learning to make the process of developing drugs faster and less expensive.
Recursion Pharmaceuticals is a clinical-stage biotech company that received a $50 million investment from Nvidia last summer.
"I think with clinical trials, there's still going to be a few years to get through the clinical trial space," Gibson said.
Before Recursion's AI-focused approach, there wasn't a clear path toward making a drug to successfully tackle this disease, he said.
"Think of it as, like, Google Street View driving around taking pictures of everything," he said.
Persons:
CNBC's Jim Cramer, Chris Gibson, Gibson, there's
Organizations:
Pharmaceuticals, Nvidia
Locations:
U.S